Evidence map›Paper›PMID 34363558›Full record

Trial reportInternational journal of clinical oncology2021

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.

Naoko Hosono, Hisayuki Yokoyama, Nobuyuki Aotsuka, Kiyoshi Ando, Hiroatsu Iida, Takayuki Ishikawa, Kensuke Usuki, Masahiro Onozawa, Masahiro Kizaki, Kohmei Kubo and 16 more

Open access · hybridAbstract readRandomized Controlled TrialEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 2 countries.

Naoko HosonoDepartment of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, 910-1193, Japan. hosono@u-fukui.ac.jp.ORCID http://orcid.org/0000-0002-6336-3250
Hisayuki YokoyamaSendai Medical Center, Sendai, Japan.
Nobuyuki AotsukaJapanese Red Cross Narita Hospital, Narita, Japan.
Kiyoshi AndoTokai University School of Medicine, Isehara, Japan.
Hiroatsu IidaNHO Nagoya Medical Center, Nagoya, Japan.
Takayuki IshikawaKobe City Medical Center General Hospital, Hyogo, Japan.
Kensuke UsukiNTT Medical Center Tokyo, Tokyo, Japan.
Masahiro OnozawaHokkaido University, Sapporo, Japan.
Masahiro KizakiSaitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Kohmei KuboAomori Prefectural Central Hospital, Aomori, Japan.
Junya KurodaKyoto Prefectural University of Medicine, Kyoto, Japan.
Yukio KobayashiInternational University of Health and Welfare (IUHW), Mita Hospital, Tokyo, Japan.
Takayuki ShimizuKeio University School of Medicine, Tokyo, Japan.
Shigeru ChibaUniversity of Tsukuba, Tsukuba, Japan.
Miho NaraAkita University, Akita, Japan.
Tomoko HataNagasaki University, Nagasaki, Japan.
Michihiro HidakaKumamoto Medical Center, Kumamoto, Japan.
Shin-Ichiro FujiwaraJichi Medical University, Shimotsuke, Japan.
Yoshinobu MaedaOkayama University Hospital, Okayama, Japan.
Yasuyoshi MoritaKindai University, Osaka, Japan.
Mikiko KusanoAstellas Pharma, Inc., Tokyo, Japan.
Qiaoyang LuAstellas Pharma US, Inc., Northbrook, IL, USA.
Shuichi MiyawakiTokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
Erhan BerrakAstellas Pharma US, Inc., Northbrook, IL, USA.
Nahla HasabouAstellas Pharma US, Inc., Northbrook, IL, USA.
Tomoki NaoeNHO Nagoya Medical Center, Nagoya, Japan.
Astellas Pharma (United States) · USNagoya Medical Center · JPAkita University · JPAomori Prefectural Central Hospital · JPAstellas Pharma (Japan) · JPHokkaido University · JPJapanese Red Cross Narita Hospital · JPJichi Medical University · JPKeio University · JPKindai University · JPKobe City Medical Center General Hospital · JPKumamoto Medical Center · JPKyoto Prefectural University of Medicine · JPMita Hospital · JPNagasaki University · JPNTT Medical Center · JPOkayama University Hospital · JPSocial Insurance Saitama Chuo Hospital · JPTohoku University · JPTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUntil recently, no effective targeted therapies for FLT3-mutated (FLT3

methodsWe evaluated the Japanese subgroup (n = 48) of the ADMIRAL trial, which included 33 patients randomized to 120-mg/day gilteritinib and 15 randomized to SC.

resultsMedian OS was 14.3 months in the gilteritinib arm and 9.6 months in the SC arm. The complete remission/complete remission with partial hematologic recovery rate was higher in the gilteritinib arm (48.5%) than in the SC arm (13.3%). After adjustment for drug exposure, fewer adverse events (AEs) occurred in the gilteritinib arm than in the SC arm. Common grade ≥ 3 AEs related to gilteritinib were febrile neutropenia (36%), decreased platelet count (27%), and anemia (24%).

conclusionFindings in Japanese patients are consistent with those of the overall ADMIRAL study population.

Indexed as

Leukemia, Myeloid, AcutePyrazinesAniline Compoundsfms-Like Tyrosine Kinase 3HumansJapanMutationAniline CompoundsFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibPyrazinesAcute myeloid leukemiaFLT3 inhibitorFLT3 mutations

Identifiers

PMID34363558
PMCPMC8522999
OpenAlexW3191376150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.